Sarepta faces regulatory, market pressure
Sarepta Therapeutics Inc, developer of the gene therapy Elevidys (delandistrogene moxeparvovec) for Duchenne muscular dystrophy, faced a further setback on 18 July after the US Food and Drug Administration was reportedly poised to stop all shipments of the therapy. This followed the deaths of three patients with the disease. Two of the deaths were reported early in the year and involved young people. The third, disclosed on 18 July, involved a 51-year-old man, according to the Bloomberg news service.
